.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Colorcon
QuintilesIMS
US Department of Justice
Chinese Patent Office
Chubb
Harvard Business School
McKinsey
Medtronic
Novartis

Generated: July 22, 2017

DrugPatentWatch Database Preview

Florbetaben f-18 - Generic Drug Details

« Back to Dashboard

What are the generic sources for florbetaben f-18 and what is the scope of florbetaben f-18 freedom to operate?

Florbetaben f-18
is the generic ingredient in one branded drug marketed by Piramal Imaging and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Florbetaben f-18 has twenty-nine patent family members in twenty-four countries.

One supplier is listed for this compound.

Summary for Generic Name: florbetaben f-18

Tradenames:1
Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list1
Clinical Trials: see list7
Patent Applications: see list8
Drug Prices:see low prices
DailyMed Link:florbetaben f-18 at DailyMed

Pharmacology for Ingredient: florbetaben f-18

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Piramal Imaging
NEURACEQ
florbetaben f-18
SOLUTION;INTRAVENOUS204677-001Mar 19, 2014RXYesYes► Subscribe► Subscribe
Piramal Imaging
NEURACEQ
florbetaben f-18
SOLUTION;INTRAVENOUS204677-001Mar 19, 2014RXYesYes7,807,135► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: florbetaben f-18

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,858,072Stilbene derivatives and their use for binding and imaging amyloid plaques► Subscribe
8,465,726Stilbene derivatives and their use for binding and imaging amyloid plaques► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: florbetaben f-18

Country Document Number Estimated Expiration
Netherlands300719► Subscribe
Eurasian Patent Organization012334► Subscribe
Eurasian Patent Organization200701299► Subscribe
South Korea101321619► Subscribe
China101123995► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FLORBETABEN F-18

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00018Denmark► SubscribePRODUCT NAME: FLORBETABEN (18F); REG. NO/DATE: EU/1/13/906/001 20140224
0150010 00142Estonia► SubscribePRODUCT NAME: FLORBETABEEN (18F);REG NO/DATE: EU/1/13/906 24.02.2014
2015 00018Denmark► SubscribePRODUCT NAME: FLORBETABEN (18F); REG. NO/DATE: EU/1/13/906/001 20140220
1 2-2015Slovakia► SubscribePRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140224
2015005Lithuania► SubscribePRODUCT NAME: FLORBETABENUM (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140220
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Fuji
McKinsey
Boehringer Ingelheim
Covington
Mallinckrodt
Merck
Medtronic
Cerilliant
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot